Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology
Recommendations
As issued by the authors
Routine aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in unselected populations is not supported by recent data; consideration should be reserved for those at highest ischemic risk
Balancing ischemic and bleeding risk requires individualized antiplatelet treatment
Original publication
Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. Published 30 June 2026. doi:10.
Summarised from the published abstract; every number is checked against it